NCT02128906 2026-04-16
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
University of Pittsburgh
Phase 2 Recruiting
Clinical Trials
208 trialsNCT07535112 2026-04-16
A Study to Learn More About How Safe BAY 3771249 is and How Well it Works in People With Advanced or Metastatic Colorectal Cancer That Has a KRAS G12D Mutation
Bayer
Phase 1 Not yet recruiting
NCT01810913 2026-04-15
Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer
National Cancer Institute (NCI)
Phase 2/3 Recruiting
NCT05910827 2026-04-15
A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers
Hummingbird Bioscience
Phase 1/2 Recruiting
NCT06589804 2026-04-15
Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
National Cancer Institute (NCI)
Phase 3 Recruiting
NCT06806852 2026-04-15
A Study to Test Whether Treatment With BI 770371 in Combination With Pembrolizumab With or Without Cetuximab Helps People With Head and Neck Cancer Compared With Pembrolizumab Alone
Boehringer Ingelheim
Phase 1 Recruiting
NCT05358249 2026-04-14
KontRASt-03
Novartis
Phase 1/2 Active not recruiting
NCT05382559 2026-04-14
A Study of ASP3082 in Adults With Advanced Solid Tumors
Astellas Pharma Inc
Phase 1 Recruiting
NCT05063552 2026-04-13
Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers
National Cancer Institute (NCI)
Phase 2/3 Active not recruiting
NCT05308446 2026-04-13
Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT05745857 2026-04-13
SLURP
University Medical Center Groningen
Phase 2 Recruiting
NCT06102902 2026-04-13
Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer
National Cancer Institute (NCI)
Phase 1 Recruiting
NCT06662786 2026-04-13
OrigAMI-2
Janssen Research & Development, LLC
Phase 3 Recruiting
NCT06750094 2026-04-13
OrigAMI-3
Janssen Research & Development, LLC
Phase 3 Recruiting
NCT06997497 2026-04-13
KANDLELIT-012
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT07042295 2026-04-13
Treatment With Amivantamab and Hyaluronidase or Cetuximab for Advanced Skin Cancer in People With a Weakened Immune System
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT07209111 2026-04-13
KANDLELIT-014
Merck Sharp & Dohme LLC
Phase 2 Recruiting
NCT07223047 2026-04-13
A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
Bristol-Myers Squibb
Phase 1/2 Recruiting
NCT07247110 2026-04-13
A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001)
Merck Sharp & Dohme LLC
Phase 1 Recruiting
NCT07252739 2026-04-13
KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)
Merck Sharp & Dohme LLC
Phase 2 Recruiting
NCT06064877 2026-04-09
FIERCE-HN
AVEO Pharmaceuticals, Inc.
Phase 3 Recruiting
NCT07286149 2026-04-09
MK-3475-01F
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
NCT07415031 2026-04-08
A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies
Mirati Therapeutics Inc.
Phase 2 Not yet recruiting
NCT05203172 2026-04-07
The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials
Pfizer
Phase 4 Recruiting
NCT05217446 2026-04-07
SEAMARK
Pfizer
Phase 2 Active not recruiting
NCT05253651 2026-04-07
MOUNTAINEER-03
Seagen Inc.
Phase 3 Recruiting
NCT07216105 2026-04-07
FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
Fate Therapeutics
Phase 1 Recruiting
NCT07506109 2026-04-07
A Phase II Study of Sintilimab Combined With Ipilimumab N01, Cetuximab and Dabrafenib in Patients With Microsatellite-Stable, BRAF V600E-Mutated Metastatic Colorectal Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Recruiting
NCT06835569 2026-04-03
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
Alterome Therapeutics, Inc.
Phase 1 Recruiting
NCT07020221 2026-04-03
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Verastem, Inc.
Phase 1/2 Recruiting
NCT07441681 2026-04-03
Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive Cisplatin
NRG Oncology
Phase 3 Not yet recruiting
NCT03370276 2026-04-02
Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Completed
NCT07468071 2026-04-02
KontRASt-R
Novartis
Phase 1/2 Not yet recruiting
NCT06369259 2026-04-01
Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-Refractory Advanced Colorectal Cancer
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT06445062 2026-04-01
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
Revolution Medicines, Inc.
Phase 1/2 Recruiting
NCT01468896 2026-03-31
Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That is Recurrent, Metastatic, or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 1/2 Active not recruiting
NCT04929223 2026-03-31
A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
Hoffmann-La Roche
Phase 1 Recruiting
NCT04722523 2026-03-30
A Study of Cemiplimab With Chemotherapy and Immunotherapy in People With Head and Neck Cancer
Memorial Sloan Kettering Cancer Center
Phase 1 Recruiting
NCT05200442 2026-03-30
A Study of VS-6766 and Cetuximab in Patients With Advanced Colorectal Cancer
University of Chicago
Phase 1/2 Recruiting
NCT07397338 2026-03-30
Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
Revolution Medicines, Inc.
Phase 1/2 Recruiting
NCT05355701 2026-03-27
A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.
Pfizer
Phase 1 Recruiting
NCT04670679 2026-03-25
FLAGSHP-1
Erasca, Inc.
Phase 1 Active not recruiting
NCT05039177 2026-03-25
HERKULES-3
Erasca, Inc.
Phase 1/2 Completed
NCT07490119 2026-03-24
Becotatug Vedotin Combined With Cetuximab in the Later-line Treatment of Metastatic RAS Wild-type Colorectal Cancer
Fudan University
Phase 2 Not yet recruiting
NCT05863195 2026-03-23
Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial
Eastern Cooperative Oncology Group
Phase 3 Recruiting
NCT06818812 2026-03-23
A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
Incyte Corporation
Phase 1 Active not recruiting
NCT06917079 2026-03-23
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Phase 1 Recruiting
NCT02215720 2026-03-20
TORERO
Gustave Roussy, Cancer Campus, Grand Paris
Phase 1 Completed
NCT01647555 2026-03-18
Radiotherapy in Association With Cetuximab in Patients Treated for an Epidermoid Cancer
Centre Oscar Lambret
Completed
NCT04375384 2026-03-18
Cetuximab After Immunotherapy for the Treatment of Head and Neck Squamous Cell Cancer
Wake Forest University Health Sciences
Phase 2 Recruiting